Coagulation assays for assessing the bypassing of factor Xa direct oral anticoagulants using VMX-C001

Background: Factor (F)Xa direct oral anticoagulants (DOACs) require rapid reversal in patients with serious bleeding or needing urgent surgery/interventions. VMX-C001 is a recombinant human FX variant under development as an FXa DOAC bypassing agent. Objectives: This study aimed to develop and evalu...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Magdolna Nagy, Tainá Gomes, René van Oerle, Tilman M. Hackeng, Fabienne J.H. Magdelijns, Yvonne M.C. Henskens, Pieter Reitsma, Ged Short, Henri M.H. Spronk, Daniël Verhoef
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2026-02-01
coleção:	Research and Practice in Thrombosis and Haemostasis
Assuntos:	anticoagulation reversal anticoagulation reversal agents blood coagulation tests direct factor Xa inhibitor dilute prothrombin time dilute Russell viper venom time
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S2475037926000336
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!